Experimental Stem Cell Therapy Shows Promise for Severe Type 1 Diabetes

A single infusion of zimislecel, an investigational cell-based treatment, helped restore insulin production in patients with severe low blood sugar events in early trial results.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Zimislecel is a stem cell-derived therapy designed to replace damaged islet cells that produce insulin
Early results from a phase 1/2 trial showed restored glucose regulation and insulin independence at one year in a small group of patients
The therapy targets people with Type 1 diabetes who experience recurrent severe hypoglycemic events and impaired awareness of low blood sugar
Zimislecel is still investigational and has not been approved by regulatory agencies

What Is Zimislecel?

Zimislecel is an experimental cell therapy developed by Vertex Pharmaceuticals for Type 1 diabetes. It uses stem cells that have been grown and differentiated into insulin-producing islet cells—the cells the body normally uses to regulate blood sugar.

The therapy is delivered as a single infusion directly into the liver through the portal vein, where the new cells are designed to engraft and take root. The treatment requires immunosuppressive medication to prevent the body from rejecting the transplanted cells.

What Did the Trial Show?

Results from the FORWARD-101 phase 1/2 trial were presented at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine. The trial followed patients for one year after receiving a single infusion of zimislecel.

According to the results, the therapy restored the body's physiologic ability to regulate glucose levels and restore glucose-responsive insulin production. At one year, some patients achieved insulin independence, meaning they no longer required insulin injections or infusions.

Who Was Studied?

The trial enrolled patients with Type 1 diabetes who experience recurrent severe hypoglycemic events—dangerous episodes of very low blood sugar. Many of these patients also had impaired hypoglycemic awareness, meaning they couldn't reliably sense when their blood sugar was dropping dangerously low.

What's Next?

Zimislecel remains investigational and has not been approved for use outside of clinical trials. The FORWARD-101 trial includes additional study phases to continue evaluating safety and effectiveness. Patients interested in clinical trials should speak with their healthcare provider about eligibility and available options.

Evidence label

Origin: healio.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.